ReviewMedComm2026
mRNA Lipid Nanoparticles for Cell Engineering in Vivo and in Vitro: Current Applications and Future Directions.
Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Messenger RNA-lipid nanoparticles (mRNA-LNPs) serve as a revolutionary platform, enabling precise and transient protein expression for both in vivo and in vitro cell engineering without genomic integration. Recent breakthroughs in mRNA design and LNP formulation have expanded their applications across immunotherapy, regenerative medicine, and genome editing. However, challenges such as off-target delivery, immunogenicity, and inadequate organ-specific targeting limit their broader therapeutic utility. This review systematically elaborates the design principles of mRNA-LNPs, including mRNA structural elements and functional lipid components that facilitate endosomal escape. It summarizes recent advances in their applications for cell engineering, both ex vivo and in vivo. Key challenges related to delivery precision and immunogenicity are thoroughly analyzed, alongside strategies to improve targeting through administration routes, surface modifications, and endogenous targeting mechanisms. The article also outlines main directions for developing next-generation mRNA-LNPs. Overall, this review will support further research on mRNA-LNPs and promote their clinical translation in the field of cell engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.